2017
DOI: 10.1016/j.neuroscience.2017.05.024
|View full text |Cite
|
Sign up to set email alerts
|

Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer’s disease

Abstract: G-protein-coupled receptors (GPCRs) are shown to be involved in Alzheimer’s disease (AD) pathogenesis. However, because GPCRs include a large family of membrane receptors, it is unclear which specific GPCR or pathway with rational ligands can become effective therapeutic targets for AD. Amylin receptor (AmR) is a GPCR that mediates several activities, such as improving glucose metabolism, relaxing cerebrovascular structure, modulating inflammatory reactions and potentially enhancing neural regeneration. Recent… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
20
0

Year Published

2018
2018
2024
2024

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 17 publications
(21 citation statements)
references
References 107 publications
1
20
0
Order By: Relevance
“…In support for a role of amylin receptor activation in memory processes are the data showing that peripherally administered amylin enhances memory in mice under training conditions in a T-maze paradigm (Flood & Morley 1992;Flood et al 1995). More recent studies show that long-term peripheral amylin treatment enriched learning and memory in mouse models of Alzheimer's disease (Zhu et al 2015;Qiu 2017;Zhu et al 2017), suggesting amylin receptors as a drug target for potential treatment of the disease (Qiu 2017). Moreover, a human study showed a positive correlation of plasma amylin and improved cognitive function in elderly population, suggesting a defensive role of amylin receptors against cognitive inclination (Qiu et al 2014).…”
Section: Discussionmentioning
confidence: 97%
“…In support for a role of amylin receptor activation in memory processes are the data showing that peripherally administered amylin enhances memory in mice under training conditions in a T-maze paradigm (Flood & Morley 1992;Flood et al 1995). More recent studies show that long-term peripheral amylin treatment enriched learning and memory in mouse models of Alzheimer's disease (Zhu et al 2015;Qiu 2017;Zhu et al 2017), suggesting amylin receptors as a drug target for potential treatment of the disease (Qiu 2017). Moreover, a human study showed a positive correlation of plasma amylin and improved cognitive function in elderly population, suggesting a defensive role of amylin receptors against cognitive inclination (Qiu et al 2014).…”
Section: Discussionmentioning
confidence: 97%
“…1A). Moreover, neither amylin nor pramlintide treatment showed significant changes in the level of insoluble Aβ 40 , but both showed significant increase in insoluble Aβ 42 compared to control (p < 0.01; Fig. 1B).…”
Section: Resultsmentioning
confidence: 86%
“…1B). Furthermore, amylin significantly increased oligomeric Aβ 40 compared to control and pramlintide (p < 0.01 and p < 0.05, respectively); however, neither treatment altered oligomeric Aβ 42 (Fig. 1C).…”
Section: Resultsmentioning
confidence: 91%
See 2 more Smart Citations